Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Integrative omics analysis of TP53 in multiple myeloma patients

View Full Paper
Ask AI
Bookmark
Share

Authors

CRCristina De RamónIMIrena MisieweiczMGMaría García‐Álvarez

Discussion

Loading...

Member takes

Overview

Integrative omics analysis reveals TP53 mutations correlate with worse prognosis and distinct p53 profiles in multiple myeloma patients.

Key Points

  • TP53 mutations negatively impact progression free survival and overall survival in multiple myeloma patients, indicating a poor prognosis.
  • A total of 10 single nucleotide variants in the TP53 gene were identified, with significant implications for disease outcomes (p ≤ 0.001).
  • Analysis utilizing Multi-Omics Factor Analysis showed distinct patient profiles based on p53 functional status that correlated with prognosis.
  • High expression levels of p53 protein were linked to specific microRNA expressions, and further studies could explore these relationships.

Cite This Study

Ramón et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db77https://doi.org/10.1182/blood-2025-2162
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Characteristics and prognostic implications of <i>TP53</i> mutations in Chinese patients with myelodysplastic syndromes2025 · 3 citations
  2. 2Multi-hit TP53 confers the poorest survival in multiple myeloma in the era of novel therapies2025 · 3 citations
  3. 3Comparative outcome and prognostic factor analysis among MDS/AML patients with TP53 mutations, snps, and wild type2025 · 4 citations
  4. 4TP53 mutations in paired bone marrow and cell-free DNA samples of patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance prospectively enrolled in the FIL_biowm study of fondazione italiana linfomi2025 · 1 citations
  5. 5TP53 and PPM1D mutations in AML: Distinct frequencies, shared pathway, and adverse prognostic trends2025